OverviewSuggest Edit

Avinger is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease, or PAD. The Company manufactures and sells a suite of products including the Lightbox imaging console, as well as the Wildcat, Kittycat2, Ocelot family of catheters, and Pantheris. 

TypePublic
Founded2007
HQRedwood City, US
Websiteavinger.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Dec 2018)75(+16%)
Job Openings2
Revenue (FY, 2018)$7.9 M(-20%)
Share Price (Mar 2019)$0.9 (-4%)

Key People/Management at Avinger

John B. Simpson

John B. Simpson

CEO
Bunty Banerjee

Bunty Banerjee

SVP, Operations
Bart Beasley

Bart Beasley

VP, Marketing, Product Development
Show more

Avinger Office Locations

Avinger has an office in Redwood City
Redwood City, US (HQ)
600 Chesapeake Dr
Show all (1)
Report incorrect company information

Avinger Financials and Metrics

Avinger Revenue

Avinger's revenue was reported to be $7.92 m in FY, 2018
USD

Revenue (FY, 2018)

7.9m

Gross profit (FY, 2018)

1.4m

Gross profit margin (FY, 2018), %

17.5%

EBIT (FY, 2018)

(22.1m)

Market capitalization (22-Mar-2019)

42.6m

Closing stock price (22-Mar-2019)

0.9

Cash (31-Dec-2018)

16.4m
Avinger's current market capitalization is $42.6 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

10.7m19.2m9.9m7.9m

Cost of goods sold

6.5m14.4m13.0m6.5m

Gross profit

4.2m4.8m(3.1m)1.4m

Gross profit Margin, %

40%25%(31%)17%
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

3.0m2.7m4.5m4.7m5.3m3.5m2.5m2.1m1.8m2.1m2.0m

Cost of goods sold

1.6m1.8m3.4m3.6m3.7m4.1m3.9m3.3m1.4m2.2m1.5m

Gross profit

1.4m971.0k1.2m1.0m1.6m(584.0k)(1.5m)(1.2m)394.0k(111.0k)543.0k

Gross profit Margin, %

46%36%26%22%30%(17%)(59%)(58%)22%(5%)27%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

43.1m36.1m5.4m16.4m

Accounts Receivable

1.6m

Inventories

5.4m8.5m4.3m3.4m

Current Assets

51.1m48.8m11.5m21.6m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

60.7m54.8m26.9m22.4m43.3m23.0m14.0m10.2m14.4m10.1m10.0m

Accounts Receivable

1.7m2.2m

Inventories

3.8m3.2m6.5m6.9m7.1m8.4m6.7m5.0m4.0m3.7m3.5m

Current Assets

67.2m60.8m38.5m33.9m55.8m34.8m23.3m17.3m20.9m16.5m15.6m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(47.3m)(56.1m)(48.7m)(27.6m)

Depreciation and Amortization

1.3m1.5m1.5m1.3m

Inventories

(2.3m)(6.1m)(1.2m)(92.0k)

Accounts Payable

84.0k470.0k(334.0k)(125.0k)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Inventories

4.0m3.8m3.2m6.5m6.9m7.1m8.4m6.7m5.0m

Accounts Payable

1.7m998.0k464.0k2.3m703.0k1.3m1.2m1.2m841.0k
USDY, 2018

Revenue/Employee

105.5k

Financial Leverage

2.5 x
Show all financial metrics
Report incorrect company information

Avinger Online and Social Media Presence

Embed Graph
Report incorrect company information

Avinger News and Updates

Avinger Provides Fourth Quarter and Full Year 2018 Shareholder Update

Pantheris Fourth Quarter Revenue Increases 18% Over Prior Quarter Pantheris Fourth Quarter Revenue Increases 18% Over Prior Quarter

Avinger to Announce Fourth Quarter and Full Year 2018 Financial Results on March 6, 2019

REDWOOD CITY, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announc…

Avinger Announces Preliminary Analysis of Results from SCAN Clinical Study

OCT Imaging with Pantheris Superior or Equivalent to IVUS on all Parameters

Avinger Announces Successful Treatment of 500th Patient with Next-Generation Pantheris Device

38% Year-over-Year Pantheris Revenue Growth in First Full Quarter of Launch 38% Year-over-Year Pantheris Revenue Growth in First Full Quarter of Launch

Avinger to Report Second Quarter 2018 Results on Monday, August 13, 2018

REDWOOD CITY, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), will announce its second quarter 2018 results for the period ended June 30, 2018 on Monday, August 13, 2018 after market close. A …
Report incorrect company information

Avinger Frequently Asked Questions

  • When was Avinger founded?

    Avinger was founded in 2007.

  • Who are Avinger key executives?

    Avinger's key executives are John B. Simpson, Bunty Banerjee and Bart Beasley.

  • How many employees does Avinger have?

    Avinger has 75 employees.

  • What is Avinger revenue?

    Latest Avinger annual revenue is $7.9 m.

  • What is Avinger revenue per employee?

    Latest Avinger revenue per employee is $105.5 k.

  • Who are Avinger competitors?

    Competitors of Avinger include Heartware International, SteadyMed Therapeutics and ResMed.

  • Where is Avinger headquarters?

    Avinger headquarters is located at 600 Chesapeake Dr, Redwood City.

  • Where are Avinger offices?

    Avinger has an office in Redwood City.

  • How many offices does Avinger have?

    Avinger has 1 office.